Literature DB >> 27494949

Slow infusion rate of doxorubicin induces higher pro-inflammatory cytokine production.

Chin-Chieh Tien1, Yi-Chi Peng2, Fwu-Lin Yang3, Yi-Maun Subeq4, Ru-Ping Lee5.   

Abstract

Different infusion rates of doxorubicin (DOX) have been used for treating human malignancies. Organ toxicity after DOX infusion is a major issue in treatment disruption. However, whether different DOX infusion rates induce different toxicity is still unknown. In this study, we examined the toxicity effects of different DOX infusion rates in the early phase of organ toxicity. Thirty-six rats were randomly divided into 5-, 15-, and 30-min infusion rate groups. A single dose of DOX (8.3 mg/kg, I.V.) was administered at different infusion rates. Blood samples were collected from the femoral artery at 1, 3, 6, 9, 12, 18, 24, 36, and 48 h after DOX administration. The blood cell count and blood biochemistry were analyzed. The liver, kidney, and heart were removed for pathological examinations after the rats were sacrificed. Our findings show that the 30-min group had higher injury markers in the liver (glutamic oxaloacetic transaminase and glutamic pyruvic transaminase), kidneys (blood urea nitrogen and creatinine), and heart (creatine phosphokinase-MB and lactate dehydrogenase), and had higher tumor necrosis factor-alpha and interleukin 6 levels than did the other groups. The 30-min group also had more severe damage according to the pathological examinations. In conclusion, slower infusion of DOX induced a higher inflammatory response and greater organ damage. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute inflammation; Cytokine; Doxorubicin; Infusion rate

Mesh:

Substances:

Year:  2016        PMID: 27494949     DOI: 10.1016/j.yrtph.2016.08.002

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  5 in total

1.  Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer.

Authors:  Xóchitl Zambrano-Estrada; Brianda Landaverde-Quiroz; Andrés A Dueñas-Bocanegra; Marco A De Paz-Campos; Gerardo Hernández-Alberto; Benjamín Solorio-Perusquia; Manuel Trejo-Mandujano; Laura Pérez-Guerrero; Evangelina Delgado-González; Brenda Anguiano; Carmen Aceves
Journal:  BMC Vet Res       Date:  2018-03-12       Impact factor: 2.741

2.  Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.

Authors:  Chhanda Bose; Sanjay Awasthi; Rajendra Sharma; Helen Beneš; Martin Hauer-Jensen; Marjan Boerma; Sharda P Singh
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

3.  Transferrin-Bound Doxorubicin Enhances Apoptosis and DNA Damage through the Generation of Pro-Inflammatory Responses in Human Leukemia Cells.

Authors:  Monika Jedrzejczyk; Katarzyna Wisniewska; Katarzyna Dominika Kania; Agnieszka Marczak; Marzena Szwed
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

4.  Tetrandrine Attenuated Doxorubicin-Induced Acute Cardiac Injury in Mice.

Authors:  Gang Li; Wen-Rui Li; Ya-Ge Jin; Qi-Qiang Jie; Cheng-Yu Wang; Lin Wu
Journal:  Biomed Res Int       Date:  2020-05-08       Impact factor: 3.411

5.  Quercetin Alleviates the Immunotoxic Impact Mediated by Oxidative Stress and Inflammation Induced by Doxorubicin Exposure in Rats.

Authors:  Mayada R Farag; Attia A A Moselhy; Amany El-Mleeh; Samira H Aljuaydi; Tamer Ahmed Ismail; Alessandro Di Cerbo; Giuseppe Crescenzo; Shimaa M Abou-Zeid
Journal:  Antioxidants (Basel)       Date:  2021-11-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.